Evommune’s oral MRGPRX2 antagonist EVO756 failed its Phase 2b trial in moderate-to-severe atopic dermatitis, missing the primary endpoint of improving EASI at Week 12 and falling short on secondary itch-related measures.
The setback follows an earlier Phase 2 failure in chronic spontaneous urticaria, where EVO756 also missed its primary endpoint, leading the company to halt further development of the drug in CSU.
Despite the string of misses in itch/urticaria indications, Evommune said it will keep studying EVO756 in other areas, including migraine, and noted the drug’s doses were safe and generally well tolerated.
EVO756 had shown earlier signs of activity in chronic inducible urticaria, but the latest AD failure appears to have ended hopes that MRGPRX2 blockade would become a broad treatment for itch-related skin disease.
Sources:
Evommune gives up on dermatitis drug after another ph. 2 fail
Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 ...
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 ...
MRGPRX2 fails key CSU test as Evommune drops urticaria ...
Evommune Announces Top Line Data from Phase 2 Trial of EVO756 ...
Evommune Announces Top-line Results from EVO756 ...
June 29, 2026 - EX-99.1 - 8-K - Evommune, Inc. (EVMN)
A Transformative Approach to Inflammatory Skin Conditions
Chronic Inflammation | MRGPRX2 Antagonist EVO756
MRGPRX2 Antagonist(BioArdis) - Drug Targets, Indications ...
Mas‐related G protein‐coupled receptor member X2 role in ...